Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VRML

Vermillion (VRML) Stock Price, News & Analysis

Vermillion logo

About Vermillion Stock (NASDAQ:VRML)

Advanced Chart

Key Stats

Today's Range
$0.07
$0.08
50-Day Range
$2.54
$4.24
52-Week Range
$0.35
$5.78
Volume
40,222 shs
Average Volume
440,144 shs
Market Capitalization
$7.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.

Receive VRML Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vermillion and its competitors with MarketBeat's FREE daily newsletter.

VRML Stock News Headlines

Camellia Vermillion
Dr. Richard L. Knutson
Trump’s Bitcoin Reserve is No Accident…
Big Swings in Crypto Right Now — and Bigger Moves Could Be Coming That kind of whiplash might scare some folks off — but for investors who've been around the block, it's usually a sign that something big is brewing.
Vermillion Elementary School
Dr. Kenneth J. Vermillion
Vermillion High School
Sanford Vermillion Medical Center
See More Headlines

VRML Stock Analysis - Frequently Asked Questions

Vermillion, Inc. (NASDAQ:VRML) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.06) earnings per share (EPS) for the quarter. The company had revenue of $1.14 million for the quarter. Vermillion had a negative net margin of 307.31% and a negative trailing twelve-month return on equity of 155.25%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vermillion investors own include CombiMatrix (CBMX), Accelerate Diagnostics (AXDX), Himax Technologies (HIMX), Charter Communications (CHTR), Idera Pharmaceuticals (IDRA), Magnachip Semiconductor (MX) and Cardiff Oncology (TROV).

Company Calendar

Last Earnings
8/08/2019
Today
5/16/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
N/A
Current Symbol
NASDAQ:VRML
Fax
N/A
Employees
43
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-15,240,000.00
Net Margins
-307.31%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.54 million
Price / Cash Flow
N/A
Book Value
$0.09 per share
Price / Book
0.87

Miscellaneous

Free Float
N/A
Market Cap
$7.59 million
Optionable
Not Optionable
Beta
3.47
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:VRML) was last updated on 5/16/2025 by MarketBeat.com Staff
From Our Partners